ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

InterMune Cuts Staff

March 26, 2007 | APPEARED IN VOLUME 85, ISSUE 13

InterMune is cutting about 116 positions, or half its staff, following its halt earlier this month of a late-stage trial of Actimmune to treat idiopathic pulmonary fibrosis (IPF), a chronic lung disease. Actimmune, the firm's synthesized version of interferon , is approved to treat two rare diseases but was found ineffective in treating IPF. InterMune says it will refocus its resources on two other drugs in its pipeline: pirfenidone, a small-molecule drug in Phase III trials for treating IPF, and a hepatitis C virus protease inhibitor in Phase Ia trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment